Free Trial
→ Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps (From Weiss Ratings) (Ad) Buy GSK Stock  Free GSK Stock Alerts

GSK (GSK) Financials

GSK logo
$40.02 +0.84 (+2.13%)
Closing price 05/29/2025 03:59 PM Eastern
Extended Trading
$39.94 -0.08 (-0.19%)
As of 05/29/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for GSK

Annual Income Statements for GSK

This table shows GSK's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Net Income / (Loss) Attributable to Common Shareholders		 3,224 6,280 18,062 5,920 7,851 6,155 4,616 2,070 1,125
Consolidated Net Income / (Loss)		 3,695 6,764 18,865 6,880 8,724 6,981 5,155 2,930 1,310
Net Income / (Loss) Continuing Operations		 3,695 6,764 5,943 4,747 6,969 6,981 5,155 2,930 1,310
Total Pre-Tax Income 		4,354 7,727 6,797 4,859 7,061 8,243 6,115 4,762 2,392
Total Operating Income		 5,035 8,595 7,769 5,882 8,166 9,224 6,985 5,521 3,206
Total Gross Profit		 27,957 27,733 23,876 22,320 22,432 29,007 26,219 26,807 22,948
Total Revenue		 39,286 38,647 35,415 33,340 33,261 44,727 39,265 40,778 34,411
Operating Revenue		 39,286 38,647 35,415 33,340 33,261 - 39,265 40,778 34,411
Total Cost of Revenue		 11,329 10,914 11,538 11,020 10,829 15,719 13,047 13,971 11,462
Operating Cost of Revenue		 11,329 10,914 11,538 11,020 10,829 15,719 13,047 13,971 11,462
Total Operating Expenses		 23,715 20,351 17,023 17,001 14,705 20,249 19,614 21,767 20,234
Selling, General & Admin Expense		 13,792 11,959 10,111 9,545 10,157 15,109 12,632 13,066 11,556
Research & Development Expense		 8,015 7,930 6,628 6,776 6,546 6,053 4,960 6,047 4,476
Other Operating Expenses / (Income)		 1,916 463 284 680 -1,998 -913 2,023 2,654 4,201
Other Special Charges / (Income)		 -7.51 -1.27 0.00 - - - - - -
Total Other Income / (Expense), net		 111 345 -57 -412 -666 -515 -489 -278 -322
Interest Expense		 838 1,009 1,062 1,038 1,194 1,208 1,017 992 908
Interest & Investment Income		 153 147 92 19 44 130 103 88 89
Other Income / (Expense), net		 796 1,208 913 608 483 563 424 625 497
Income Tax Expense		 659 963 854 112 92 1,263 961 1,832 1,082
Net Income / (Loss) Discontinued Operations		 0.00 0.00 12,922 2,133 1,755 - - - -
Net Income / (Loss) Attributable to Noncontrolling Interest		 -471 -484 -803 -960 -873 -826 -539 -861 -185
Basic Earnings per Share		 $1.58 $3.10 $5.82 $1.10 $1.97 $0.94 $0.74 $0.42 $0.19
Weighted Average Basic Shares Outstanding		 4.31B 4.31B 4.31B 5.39B 5.39B 5.38B 5.38B - -
Diluted Earnings per Share		 $1.56 $3.06 $11.99 $1.61 $2.54 $0.93 $0.73 $0.42 $0.19
Weighted Average Diluted Shares Outstanding		 4.31B 4.31B 4.31B 5.39B 5.39B 5.38B 5.38B - -
Weighted Average Basic & Diluted Shares Outstanding		 4.31B 4.31B 4.31B 5.39B 5.39B 5.38B 5.38B - -

Quarterly Income Statements for GSK

No quarterly income statements for GSK are available.

Annual Cash Flow Statements for GSK

This table details how cash moves in and out of GSK's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents		 750 -596 -659 -14,351 -10,781 1,095 610 -1,223 -1,436 12,796
Net Cash From Operating Activities		 8,206 8,624 8,941 -4,821 6,551 10,627 10,728 9,345 8,016 12,796
Net Cash From Continuing Operating Activities		 8,206 8,624 8,012 -4,821 6,551 10,627 10,728 9,345 8,016 12,796
Net Income / (Loss) Continuing Operations		 3,695 6,764 5,943 0.00 0.00 6,981 5,155 2,930 1,310 12,796
Consolidated Net Income / (Loss)		 3,695 6,764 5,943 - - 6,981 5,155 2,930 1,310 12,796
Non-Cash Adjustments To Reconcile Net Income		 6,148 3,553 3,651 -2,912 5,909 5,650 7,263 8,226 8,691 -
Changes in Operating Assets and Liabilities, net		 -1,636 -1,692 -1,582 -1,909 642 -2,004 -1,689 -1,810 -1,985 -
Net Cash From Discontinued Operating Activities		 0.00 0.00 929 - - - - - - -
Net Cash From Investing Activities		 -1,539 -2,033 -10,594 -1,104 -1,284 -7,094 -1,978 -1,949 -1,566 0.00
Net Cash From Continuing Investing Activities		 -1,539 -2,033 -6,016 -1,104 -1,284 -2,487 -1,978 -1,934 -1,462 0.00
Purchase of Property, Plant & Equipment		 -3,734 -2,987 -2,727 -1,283 -1,351 -2,866 -1,712 -2,975 -2,059 -
Acquisitions		 -1,008 -1,857 -3,754 0.00 0.00 - -13 0.00 21 -
Purchase of Investments		 -183 -157 -174 - - -342 -969 -108 -118 -
Sale of Property, Plant & Equipment		 245 51 413 178 67 661 540 444 470 -
Divestitures		 -23 62 -52 - - - 33 381 89 -
Sale and/or Maturity of Investments		 3,142 2,496 372 - - 101 246 359 136 -
Net Cash From Discontinued Investing Activities		 0.00 0.00 -4,578 - - - - - - -
Net Cash From Financing Activities		 -5,917 -7,188 994 -8,425 -16,048 -2,438 -8,139 -8,619 -7,887 0.00
Net Cash From Continuing Financing Activities		 -5,917 -7,188 -11,172 -8,425 -16,048 -6,539 -8,243 -7,730 -9,045 0.00
Repayment of Debt		 -3,096 -4,107 -9,321 -3,110 -5,105 -6,982 -3,645 -4,647 -1,993 -
Payment of Dividends		 -3,060 -2,863 -4,187 -5,721 -6,035 -5,720 -5,729 -6,329 -6,643 -
Issuance of Debt		 1,346 284 1,238 406 -4,908 6,352 12,916 3,017 0.00 -
Issuance of Common Equity		 25 13 30 - - 68 94 76 110 -
Other Financing Activities, net		 173 435 464 - - -257 -11,879 154 -519 -
Net Cash From Discontinued Financing Activities		 0.00 0.00 12,166 - - - - - - -

Quarterly Cash Flow Statements for GSK

No quarterly cash flow statements for GSK are available.

Annual Balance Sheets for GSK

This table presents GSK's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Total Assets		 74,454 75,190 72,638 106,789 109,845 105,598 73,975 76,165 72,888
Total Current Assets		 21,282 23,758 25,083 25,210 27,652 25,827 21,565 21,489 20,616
Cash & Equivalents		 4,846 3,741 4,496 5,770 8,593 6,237 4,935 5,178 6,041
Short-Term Investments		 136 166 229 254 208 558 240 92 -
Accounts Receivable		 8,559 9,411 8,518 10,611 9,494 9,543 8,183 8,105 7,434
Inventories, net		 7,098 7,103 6,215 7,807 8,334 9,037 6,976 7,507 6,294
Current Deferred & Refundable Income Taxes		 612 475 489 656 916 347 292 349 279
Plant, Property, & Equipment, net		 11,553 11,494 10,788 13,408 13,897 13,712 14,088 14,671 12,288
Plant, Property & Equipment, gross		 11,553 11,494 10,788 13,408 13,897 13,712 14,088 14,671 12,288
Total Noncurrent Assets		 41,619 39,938 36,767 68,171 68,296 66,059 39,687 40,005 45,628
Long-Term Investments		 1,498 1,519 1,861 2,989 4,676 2,850 1,985 1,487 1,649
Goodwill		 8,742 8,679 8,509 14,245 14,472 13,995 7,375 7,746 7,359
Intangible Assets		 19,426 18,819 17,292 40,607 40,731 41,018 21,915 23,724 23,164
Noncurrent Deferred & Refundable Income Taxes		 8,460 7,708 6,833 7,044 5,855 5,428 4,952 5,128 5,396
Other Noncurrent Operating Assets		 3,492 3,213 2,272 3,286 2,562 2,768 3,460 1,920 7,795
Total Liabilities & Shareholders' Equity		 65,338 66,701 72,638 106,789 109,845 105,598 73,975 67,827 77,965
Total Liabilities		 58,069 58,885 60,445 77,977 81,428 81,274 69,297 71,451 66,765
Total Current Liabilities		 27,167 26,847 27,548 31,955 30,248 31,868 28,653 35,892 21,703
Short-Term Debt		 2,941 3,585 4,773 4,861 5,087 9,167 8,446 3,816 5,094
Accounts Payable		 19,201 21,138 19,641 23,698 21,633 19,795 18,815 28,328 14,760
Current Deferred & Payable Income Tax Liabilities		 880 - 569 660 744 833 - 1,344 1,610
Other Current Liabilities		 2,677 145 2,565 2,735 2,783 2,072 162 950 239
Total Noncurrent Liabilities		 30,902 32,038 32,898 46,023 51,180 49,406 40,644 35,559 47,660
Long-Term Debt		 18,327 19,376 20,573 27,774 31,992 31,259 32,767 19,269 18,087
Noncurrent Deferred & Payable Income Tax Liabilities		 478 492 502 5,044 5,157 5,299 1,819 2,441 2,386
Noncurrent Employee Benefit Liabilities		 2,334 2,982 3,115 4,203 4,985 4,581 3,981 4,781 5,046
Other Noncurrent Operating Liabilities		 2,115 2,041 8,708 9,003 9,046 8,267 2,077 2,184 22,141
Total Equity & Noncontrolling Interests		 16,385 16,305 12,193 28,812 28,418 24,324 4,678 4,713 8,601
Total Preferred & Common Equity		 17,117 17,008 12,799 20,324 28,418 39,437 4,817 -92 3,865
Preferred Stock		 4,349 4,398 4,154 4,456 4,481 4,206 3,938 4,078 -
Total Common Equity		 12,769 12,610 8,645 15,868 15,441 10,907 879 -4,170 3,865
Common Stock		 1,688 1,718 1,627 1,818 1,838 1,784 1,714 1,814 1,656
Retained Earnings		 9,761 9,225 5,269 10,724 9,225 6,003 -3,460 -8,750 -6,652
Other Equity Adjustments		 1,320 1,668 1,749 3,325 4,377 3,121 2,626 2,765 8,862
Noncontrolling Interest		 -732 -703 -606 8,487 8,496 9,212 -139 4,805 4,736

Quarterly Balance Sheets for GSK

This table presents GSK's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q4 2023 Q4 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets		 74,454 75,190 72,638
Total Current Assets		 21,282 23,758 25,083
Cash & Equivalents		 4,846 3,741 4,496
Short-Term Investments		 136 166 229
Accounts Receivable		 8,559 9,411 8,518
Inventories, net		 7,098 7,103 6,215
Current Deferred & Refundable Income Taxes		 612 475 489
Plant, Property, & Equipment, net		 11,553 11,494 10,788
Plant, Property & Equipment, gross		 11,553 11,494 10,788
Total Noncurrent Assets		 41,619 39,938 36,767
Long-Term Investments		 1,498 1,519 1,861
Goodwill		 8,742 8,679 8,509
Intangible Assets		 19,426 18,819 17,292
Noncurrent Deferred & Refundable Income Taxes		 8,460 7,708 6,833
Other Noncurrent Operating Assets		 3,492 3,213 2,272
Total Liabilities & Shareholders' Equity		 65,338 66,701 72,638
Total Liabilities		 58,069 58,885 60,445
Total Current Liabilities		 27,167 26,847 27,548
Short-Term Debt		 2,941 3,585 4,773
Accounts Payable		 19,201 21,138 19,641
Current Deferred & Payable Income Tax Liabilities		 880 - 569
Other Current Liabilities		 2,677 145 2,565
Total Noncurrent Liabilities		 30,902 32,038 32,898
Long-Term Debt		 18,327 19,376 20,573
Noncurrent Deferred & Payable Income Tax Liabilities		 478 492 502
Noncurrent Employee Benefit Liabilities		 2,334 2,982 3,115
Other Noncurrent Operating Liabilities		 2,115 2,041 8,708
Total Equity & Noncontrolling Interests		 16,385 16,305 12,193
Total Preferred & Common Equity		 17,117 17,008 12,799
Preferred Stock		 4,349 4,398 4,154
Total Common Equity		 12,769 12,610 8,645
Common Stock		 1,688 1,718 1,627
Retained Earnings		 9,761 9,225 5,269
Other Equity Adjustments		 1,320 1,668 1,749
Noncontrolling Interest		 -732 -703 -606

Annual Metrics And Ratios for GSK

This table displays calculated financial ratios and metrics derived from GSK's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 1.65% 9.13% 6.22% 0.24% -25.64% 13.91% -3.71% 18.50% 0.00% 0.00%
EBITDA Growth		 -40.52% 12.91% 33.79% -24.97% -11.63% 32.09% 20.55% 66.00% 118.94% 0.00%
EBIT Growth		 -40.52% 12.91% 33.79% -24.97% -11.63% 32.09% 20.55% 66.00% 118.94% 0.00%
NOPAT Growth		 -43.20% 10.75% 18.22% -28.70% 3.19% 32.66% 73.32% 93.50% 108.98% 0.00%
Net Income Growth		 -45.37% -64.15% 174.22% -21.14% 24.98% 35.43% 75.92% 123.61% 0.00% 0.00%
EPS Growth		 -49.03% -74.52% 643.49% -21.14% 24.98% 27.02% 135.16% 125.16% -92.94% 0.00%
Operating Cash Flow Growth		 -4.85% -3.54% 285.46% -173.59% -38.35% -0.94% 14.80% 16.58% -37.35% 0.00%
Free Cash Flow Firm Growth		 156.82% -118.40% 523.83% -52.11% 173.29% -602.20% 259.60% 91.40% 0.00% 0.00%
Invested Capital Growth		 2.01% 52.87% -50.66% 0.79% -5.61% 71.98% 9.82% 22.22% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 71.16% 71.76% 67.42% 66.95% 67.44% 64.85% 66.77% 65.74% 66.69% 0.00%
EBITDA Margin		 14.84% 25.37% 24.52% 19.46% 26.00% 21.88% 18.87% 15.07% 10.76% 0.00%
Operating Margin		 12.82% 22.24% 21.94% 17.64% 24.55% 20.62% 17.79% 13.54% 9.32% 0.00%
EBIT Margin		 14.84% 25.37% 24.52% 19.46% 26.00% 21.88% 18.87% 15.07% 10.76% 0.00%
Profit (Net Income) Margin		 9.41% 17.50% 53.27% 20.63% 26.23% 15.61% 13.13% 7.19% 3.81% 0.00%
Tax Burden Percent		 84.87% 87.53% 277.56% 141.59% 123.56% 84.68% 84.29% 61.53% 54.77% -65.45%
Interest Burden Percent		 74.66% 78.82% 78.29% 74.87% 81.64% 84.23% 82.53% 77.47% 64.61% 100.00%
Effective Tax Rate		 15.13% 12.47% 12.56% 2.31% 1.30% 15.32% 15.71% 38.47% 45.23% 0.00%
Return on Invested Capital (ROIC)		 10.72% 23.05% 17.39% 11.03% 15.08% 17.96% 19.27% 12.83% 14.74% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 8.26% 18.92% 82.41% 15.85% 17.53% 15.10% 16.44% 10.48% 8.89% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 11.89% 24.42% 74.63% 13.02% 18.01% 30.18% 90.50% 31.18% 15.73% 0.00%
Return on Equity (ROE)		 22.61% 47.47% 92.02% 24.04% 33.08% 48.14% 109.77% 44.01% 30.47% 0.00%
Cash Return on Invested Capital (CROIC)		 8.73% -18.77% 85.23% 10.24% 20.85% -34.97% 9.91% -7.17% -185.26% 0.00%
Operating Return on Assets (OROA)		 7.79% 13.26% 9.68% 5.99% 8.03% 10.90% 9.87% 8.25% 5.08% 0.00%
Return on Assets (ROA)		 4.94% 9.15% 21.03% 6.35% 8.10% 7.77% 6.87% 3.93% 1.80% 0.00%
Return on Common Equity (ROCE)		 17.55% 35.41% 55.01% 13.15% 16.53% 19.56% -38.47% -1.01% 13.69% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 21.59% 39.77% 147.40% 33.85% 30.70% 17.70% 110.19% -3,189.71% 33.90% 0.00%
Net Operating Profit after Tax (NOPAT)		 4,273 7,524 6,793 5,746 8,060 7,811 5,888 3,397 1,756 -19,551
NOPAT Margin		 10.88% 19.47% 19.18% 17.24% 24.23% 17.46% 15.00% 8.33% 5.10% 0.00%
Net Nonoperating Expense Percent (NNEP)		 2.46% 4.13% -65.02% -4.82% -2.45% 2.86% 2.84% 2.36% 5.85% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 11.35% 19.16% 18.10% - - - - - - -
Cost of Revenue to Revenue		 28.84% 28.24% 32.58% 33.05% 32.56% 35.15% 33.23% 34.26% 33.31% 0.00%
SG&A Expenses to Revenue		 35.11% 30.95% 28.55% 28.63% 30.54% 33.78% 32.17% 32.04% 33.58% 0.00%
R&D to Revenue		 20.40% 20.52% 18.72% 20.32% 19.68% 13.53% 12.63% 14.83% 13.01% 0.00%
Operating Expenses to Revenue		 60.36% 52.66% 48.07% 50.99% 44.21% 45.27% 49.95% 53.38% 58.80% 0.00%
Earnings before Interest and Taxes (EBIT)		 5,831 9,803 8,682 6,489 8,649 9,787 7,409 6,147 3,703 -19,551
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 5,831 9,803 8,682 6,489 8,649 9,787 7,409 6,147 3,703 -19,551
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 5.65 5.97 9.75 6.82 5.43 9.51 91.19 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 1.84 1.95 2.38 3.25 2.52 2.32 2.04 0.00 0.00 0.00
Price to Earnings (P/E)		 22.37 11.99 4.67 18.29 10.68 16.85 17.37 0.00 0.00 0.00
Dividend Yield		 5.87% 4.02% 5.23% 5.47% 6.58% 5.29% 7.15% 8.06% 7.39% 7.93%
Earnings Yield		 4.47% 8.34% 21.42% 5.47% 9.36% 5.94% 5.76% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.25 2.45 4.13 2.77 2.32 2.69 3.44 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 2.30 2.50 3.01 4.34 3.62 3.31 2.80 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 15.53 9.85 12.28 22.32 13.93 15.11 14.85 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 15.53 9.85 12.28 22.32 13.93 15.11 14.85 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 21.19 12.83 15.70 25.20 14.94 18.94 18.68 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 11.03 11.19 11.93 0.00 18.38 13.92 10.25 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 26.01 0.00 3.20 27.13 10.81 0.00 36.32 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 1.30 1.41 2.08 1.13 1.30 1.66 7.10 4.90 2.70 0.00
Long-Term Debt to Equity		 1.12 1.19 1.69 0.96 1.13 1.29 5.52 4.09 2.10 0.00
Financial Leverage		 1.44 1.29 0.91 0.82 1.03 2.00 5.51 2.98 1.77 0.00
Leverage Ratio		 4.58 5.19 4.38 3.79 4.08 6.19 15.99 11.19 8.47 0.00
Compound Leverage Factor		 3.42 4.09 3.43 2.83 3.33 5.22 13.19 8.67 5.48 0.00
Debt to Total Capital		 56.48% 58.48% 67.52% 53.11% 56.61% 62.43% 87.65% 83.05% 72.94% 0.00%
Short-Term Debt to Total Capital		 7.81% 9.13% 12.71% 7.91% 7.77% 14.16% 19.48% 13.73% 16.03% 0.00%
Long-Term Debt to Total Capital		 48.67% 49.35% 54.80% 45.20% 48.84% 48.28% 68.17% 69.32% 56.91% 0.00%
Preferred Equity to Total Capital		 11.55% 11.20% 11.07% 7.25% 6.84% 6.50% 10.39% 14.67% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -1.95% -1.79% -1.62% 13.81% 12.97% 14.23% -0.37% 17.29% 14.90% 0.00%
Common Equity to Total Capital		 33.91% 32.12% 23.03% 25.82% 23.57% 16.84% 2.32% -15.00% 12.16% 0.00%
Debt to EBITDA		 3.65 2.34 2.92 5.03 4.29 4.13 4.48 3.76 6.26 0.00
Net Debt to EBITDA		 2.54 1.79 2.16 3.64 2.73 3.15 3.52 2.66 4.18 0.00
Long-Term Debt to EBITDA		 3.14 1.98 2.37 4.28 3.70 3.19 3.49 3.13 4.88 0.00
Debt to NOPAT		 4.98 3.05 3.73 5.68 4.60 5.18 5.64 6.80 13.20 0.00
Net Debt to NOPAT		 3.46 2.33 2.76 4.11 2.93 3.94 4.42 4.81 8.82 0.00
Long-Term Debt to NOPAT		 4.29 2.58 3.03 4.83 3.97 4.00 4.39 5.67 10.30 0.00
Altman Z-Score		 1.62 1.83 1.78 1.41 1.27 1.51 1.37 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 22.36% 25.41% 40.22% 45.29% 50.04% 59.36% 135.04% 102.29% 55.06% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.78 0.88 0.91 0.79 0.91 0.81 0.75 0.60 0.95 0.00
Quick Ratio		 0.50 0.50 0.48 0.52 0.60 0.51 0.47 0.37 0.62 0.00
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 3,481 -6,126 33,298 5,338 11,146 -15,209 3,028 -1,897 -22,071 0.00
Operating Cash Flow to CapEx		 235.25% 293.75% 386.38% -436.55% 510.32% 481.97% 915.33% 369.35% 504.43% 0.00%
Free Cash Flow to Firm to Interest Expense		 4.16 -6.07 31.37 5.14 9.34 -12.58 2.98 -1.91 -24.30 0.00
Operating Cash Flow to Interest Expense		 9.80 8.55 8.42 -4.64 5.49 8.79 10.55 9.43 8.83 0.00
Operating Cash Flow Less CapEx to Interest Expense		 5.63 5.64 6.24 -5.71 4.41 6.97 9.40 6.87 7.08 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.53 0.52 0.39 0.31 0.31 0.50 0.52 0.55 0.47 0.00
Accounts Receivable Turnover		 4.37 4.31 3.70 3.32 3.49 5.05 4.82 5.25 4.63 0.00
Inventory Turnover		 1.60 1.64 1.65 1.37 1.25 1.87 1.70 2.02 1.82 0.00
Fixed Asset Turnover		 3.41 3.47 2.93 2.44 2.41 3.22 2.73 3.03 2.80 0.00
Accounts Payable Turnover		 0.56 0.54 0.53 0.49 0.52 0.83 0.56 0.65 0.78 0.00
Days Sales Outstanding (DSO)		 83.48 84.66 98.58 110.06 104.46 72.33 75.71 69.55 78.86 0.00
Days Inventory Outstanding (DIO)		 228.77 222.69 221.78 267.30 292.75 195.57 214.23 180.28 200.43 0.00
Days Payable Outstanding (DPO)		 649.83 681.87 685.48 750.71 698.20 437.44 646.40 562.85 470.00 0.00
Cash Conversion Cycle (CCC)		 -337.58 -374.52 -365.12 -373.35 -300.99 -169.54 -356.47 -313.02 -190.72 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 40,259 39,466 25,817 52,322 51,913 55,000 31,981 29,121 23,826 0.00
Invested Capital Turnover		 0.99 1.18 0.91 0.64 0.62 1.03 1.29 1.54 2.89 0.00
Increase / (Decrease) in Invested Capital		 792 13,649 -26,505 409 -3,087 23,019 2,860 5,295 23,826 0.00
Enterprise Value (EV)		 90,533 96,516 106,629 144,819 120,443 147,902 110,001 0.00 0.00 0.00
Market Capitalization		 72,128 75,287 84,322 108,252 83,864 103,704 80,157 0.00 0.00 0.00
Book Value per Share		 $2.96 $2.92 $1.60 $2.95 $2.87 $2.03 $0.16 $0.00 $0.00 $0.00
Tangible Book Value per Share		 ($3.57) ($3.45) ($3.18) ($7.24) ($7.39) ($8.20) ($5.29) $0.00 $0.00 $0.00
Total Capital		 37,653 39,265 37,539 61,447 65,497 64,750 37,883 27,799 31,783 0.00
Total Debt		 21,268 22,960 25,346 32,635 37,079 40,426 33,205 23,085 23,181 0.00
Total Long-Term Debt		 18,327 19,376 20,573 27,774 31,992 31,259 25,825 19,269 18,087 0.00
Net Debt		 14,789 17,534 18,759 23,622 23,602 30,780 26,045 16,328 15,490 0.00
Capital Expenditures (CapEx)		 3,488 2,936 2,314 1,104 1,284 2,205 1,172 2,530 1,589 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7,926 -3,411 -2,418 -7,907 -6,310 -3,669 -4,883 -15,857 -2,034 0.00
Debt-free Net Working Capital (DFNWC)		 -2,944 496 2,308 -1,883 2,491 3,126 292 -10,587 4,007 0.00
Net Working Capital (NWC)		 -5,885 -3,089 -2,465 -6,745 -2,596 -6,041 -7,088 -14,403 -1,087 0.00
Net Nonoperating Expense (NNE)		 578 760 -12,072 -1,133 -664 830 733 467 445 -32,347
Net Nonoperating Obligations (NNO)		 23,874 23,162 13,624 23,510 23,496 30,676 27,303 24,408 15,225 0.00
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -20.17% -8.83% -6.83% -23.72% -18.97% -8.20% -12.44% -38.89% -5.91% 0.00%
Debt-free Net Working Capital to Revenue		 -7.49% 1.28% 6.52% -5.65% 7.49% 6.99% 0.74% -25.96% 11.64% 0.00%
Net Working Capital to Revenue		 -14.98% -7.99% -6.96% -20.23% -7.81% -13.51% -18.05% -35.32% -3.16% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.58 $1.22 $4.49 $0.00 $1.17 $0.95 $0.75 $0.41 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 4.31B 4.31B 4.31B 0.00 5.30B 5.30B 5.29B 0.00 0.00 0.00
Adjusted Diluted Earnings per Share		 $1.56 $1.20 $10.67 $0.00 $1.16 $0.94 $0.74 $0.41 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 4.31B 4.31B 4.31B 0.00 5.30B 5.30B 5.29B 0.00 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.31B 4.31B 4.31B 0.00 5.30B 5.30B 5.29B 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 4,267 7,522 6,793 5,746 8,060 7,811 5,888 3,397 1,756 -13,686
Normalized NOPAT Margin		 10.86% 19.46% 19.18% 17.24% 24.23% 17.46% 15.00% 8.33% 5.10% 0.00%
Pre Tax Income Margin		 11.08% 19.99% 19.19% 14.57% 21.23% 18.43% 15.57% 11.68% 6.95% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 6.96 9.71 8.18 6.25 7.25 8.10 7.29 6.20 4.08 0.00
NOPAT to Interest Expense		 5.10 7.45 6.40 5.54 6.75 6.46 5.79 3.43 1.93 0.00
EBIT Less CapEx to Interest Expense		 2.80 6.80 6.00 5.19 6.17 6.27 6.14 3.65 2.33 0.00
NOPAT Less CapEx to Interest Expense		 0.94 4.55 4.22 4.47 5.68 4.64 4.64 0.87 0.18 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 82.82% 42.33% 22.19% 83.16% 69.18% 81.95% 111.15% 216.00% 506.97% 0.00%
Augmented Payout Ratio		 82.82% 42.33% 22.19% 83.16% 69.18% 81.95% 111.15% 216.00% 506.97% 0.00%

Quarterly Metrics And Ratios for GSK

No quarterly metrics and ratios for GSK are available.

Frequently Asked Questions About GSK's Financials

When does GSK's financial year end?

According to the most recent income statement we have on file, GSK's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has GSK's net income changed over the last 8 years?

GSK's net income appears to be on an upward trend, with a most recent value of $3.69 billion in 2024, rising from $1.31 billion in 2016. The previous period was $6.76 billion in 2023. See where experts think GSK is headed by visiting GSK's forecast page.

What is GSK's operating income?
GSK's total operating income in 2024 was $5.03 billion, based on the following breakdown:
  • Total Gross Profit: $27.96 billion
  • Total Operating Expenses: $23.71 billion
How has GSK revenue changed over the last 8 years?

Over the last 8 years, GSK's total revenue changed from $34.41 billion in 2016 to $39.29 billion in 2024, a change of 14.2%.

How much debt does GSK have?

GSK's total liabilities were at $58.07 billion at the end of 2024, a 1.4% decrease from 2023, and a 13.0% decrease since 2016.

How much cash does GSK have?

In the past 8 years, GSK's cash and equivalents has ranged from $3.74 billion in 2023 to $8.59 billion in 2020, and is currently $4.85 billion as of their latest financial filing in 2024.

How has GSK's book value per share changed over the last 9 years?

Over the last 9 years, GSK's book value per share changed from 0.00 in 2015 to 2.96 in 2024, a change of 296.1%.


Related Companies

This page (NYSE:GSK) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners
Buffett’s Next Move Could Shock Wall Street
In just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next...
Golden Portfolio | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...
Weiss Ratings | Sponsored
URGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?
According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...
Paradigm Press | Sponsored
We’ve Entered the Most Bullish Phase of the Cycle
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...
Crypto Swap Profits | Sponsored
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...
Brownstone Research | Sponsored
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...
Banyan Hill Publishing | Sponsored